11,457
Total Claims
$2.6M
Drug Cost
1,208
Beneficiaries
$2,142
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+41%
Cost per patient vs peers
$2,142 vs $1,524 avg
+44%
Brand preference vs peers
19.6% vs 13.7% avg
Brand vs Generic
80% generic
Brand: 2,251 claims · $2.4M
Generic: 9,206 claims · $211K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 859 | $919K |
| Sacubitril/Valsartan | 365 | $380K |
| Rivaroxaban | 261 | $241K |
| Dronedarone Hcl | 166 | $229K |
| Dapagliflozin Propanediol | 186 | $224K |
| Empagliflozin | 155 | $188K |
| Evolocumab | 88 | $72K |
| Alirocumab | 35 | $33K |
| Ezetimibe | 753 | $25K |
| Ticagrelor | 32 | $21K |
| Rosuvastatin Calcium | 868 | $17K |
| Bempedoic Acid | 16 | $16K |
| Metoprolol Succinate | 851 | $16K |
| Torsemide | 733 | $16K |
| Colchicine | 123 | $12K |
Prescribing Profile
62
Unique Drugs
$2.0M
Patient Profile
76
Avg Age
48%
Female
1.91
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data